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Introduction
Osteonecrosis of the jaws associated with the use of 
bisphosphonates is one of the most serious complications 
of long-term therapy with bisphosphonates associated 
to oral surgical procedures, such as dental implants 
placement.1 Osteonecrosis is defined as bone exposure in 
the maxillofacial region that does not heal within 8 weeks 
after its identification. It is associated with the use of an 
antiresorptive agent (bisphosphonate or denosumab), 
without history of radiation therapy for the craniofacial 
region.2 The treatment of this condition is extremely 
difficult. Currently, antibiotic therapy, minimally invasive 
surgery, and lower-level laser therapy (LLLT) during the 
early stages have been considered the gold standard for 
medication-related osteonecrosis of the jaw (MRONJ).3 
Case Presentation
A 65-year-old female patient was referred to the oral and 
maxillofacial surgery team from Araçatuba Dental School 
2 months after a dental implant installation, complaining 
about its mobility. During anamnesis, hypertension 
and diabetes were reported, both controlled by daily 
medication, and use of alendronate (70 mg/d for 5 years) 
for prevention of osteoporosis. The clinical examination 
showed an accentuated mobility of the dental implant in 
the region of tooth 16, bone exposure in the periimplant 
region with vestibular and palatal extensions, purulent 
secretion and bad odor, and absence of remission of signs 
and symptoms (Figure 1A). After careful evaluation of the 
medical history and clinical examination, stage 2 MRONJ 
was diagnosed, characterized by the presence of exposure 
and necrotic bone associated with symptomatic infection 
and purulent discharge. The treatment proposed for this 
case was the implant removal (Figure 1B), followed by 
the initiation of 3 sessions per week of LLLT in the area 
of necrosis over 8 weeks, associated with administration 
of clindamycin (300 mg every 8 houes) and regular 
mouthwash with chlorhexidine 0.12% for the same 
period. An InGaAlP laser was used (Photon lase, DMC; 
wavelength 810 nm, power 100 mW, frequency 50/60 
Hz, and power density 0.3–0.5 W/cm²). The “alveolitis” 
program was used, corresponding to 50 J/cm² and applied 
at 3 points of the lesion (distobuccal, mesiobuccal, and 
palatal), 1–2 mm from the tissue, 3 times in each spot for 
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Case Presentation: This study aimed to report a case of medication related osteonecrosis of the 
jaw (MRONJ) of a 65-year-old female patient referred to the Oral and Maxillofacial Surgery 
team from Araçatuba Dental School, complaining about mobility of a previously dental implant 
placed on the posterior maxillary region. Clinical examination revealed an extensive necrosis 
area around the implant region. The patient reported bisphosphonate therapy with sodium 
alendronate for prevention of osteoporosis 5 years ago. A diagnosis of MRONJ was reached and 
the treatment decided was to remove the dental implant damaged and use the lower-level laser 
therapy (LLLT) associated with antibiotic therapy with clindamycin 300 mg and mouth rinses 
with chlorhexidine 0.12%. 
Conclusion: Six months after the treatment with LLLT a complete healing of the affected area 
was observed and 12 months after treatment the patient was rehabilitated with fixed dental 
prosthesis and showed excellent tissue healing of the necrosis areas. It was concluded that the 
use of LLLT showed to be a good option in the treatment of MRONJ. 
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14 seconds each. The “traumatic lesion” program was also 
used, corresponding to 25 J/cm² applied at 3 points of the 
lesion (distobuccal, mesiobuccal, and palatal), 1–2 mm 
from the tissue, 3 times in each spot for 7 seconds each. 
After 8 weeks of laser therapy, significant improvement 
was observed in the residual repair with cessation of 
purulent secretion and reduction of the necrosis area. 
At 6-month follow up after the completion of the laser 
and antibiotic therapy sessions, complete tissue healing 
and absence of purulent secretion were noted (Figure 
1C). On radiographic examination after this period, it 
was possible to observe a region of good bone healing in 
evolution (Figure 1D). Twelve months after treatment was 
started, the patient was rehabilitated with a fixed dental 
prosthesis and presented great healing with no complaints 
(Figure 1E). 
Discussion
Dentoalveolar surgery for patients using oral 
bisphosphonates for more than 4 years is considered a 
risk factor for MRONJ. Thus, the suspension of the drug 
2 months before the surgical procedure is proposed.4 
However, in this case the patient did not report the use 
of sodium alendronate at the implant placement time. 
The literature shows evidence of high rates of implant 
loss and a high incidence of osteonecrosis in patients 
submitted to implant surgery associated with the use of 
bisphosphonates, and the risk of developing osteonecrosis 
as well as implant failure exists; however, it is greater in 
patients receiving intravenous bisphosphonates such as 
zoledronic acid.5
Several treatments for MRONJ have been proposed, 
such as surgical, conservative, and combined surgical–
conservative therapies. The treatment indication varies 
according to the stage of the lesion. The most advanced 
stages indicate a need for the most aggressive approach.6 
However, no one has demonstrated total efficacy.2 Laser 
therapy performs very well for patients with at least stage 
2 MRONJ.7 The patient in this study presented stage 2 
MRONJ, thus we opted to use LLLT, which has been shown 
to be a promising adjuvant treatment for this condition due 
its ability to modulate the cellular metabolism, improve 
the wound healing, and relieve pain. The biostimulating 
effect of laser irradiation expands the organic bone matrix 
and increases the mitotic index of osteoblasts, stimulating 
its proliferation and differentiation and increasing the 
number of differentiated osteoblastic cells and their 
activity. In addition, LLLT is a noninvasive method with 
antibacterial and biostimulating effects on soft and hard 
tissues and presents proangiogenic factors.3
This study showed a successful treatment of MRONJ 
using a protocol composed of antibiotic therapy with 
clindamycin, minimally invasive surgery, and LLLT. 
Thus, we conclude that it is extremely important to 
obtain a complete medical history of a patient, and if 
bisphosphonate therapy is confirmed, then parameters 
such as duration of treatment and route of administration 
should be considered for planning a surgical procedure 
as guided by the recommendations of the American 
Association of Oral and Maxillofacial Surgeons (AAOMS). 
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Figure 1. (A) Clinical aspect of MRONJ during examination. It is possible observe necrosis areas affecting the implant region (arrow) 
extending to the palatal region (arrow). (B) Dental implant removed due necrosis presence and excessive mobility. (C) Clinical aspect on 6 
months of follow-up after laser therapy treatment, which shows a complete healing and absence of necrosis areas. (D) Ortopanthomography 
six months after treatment with laser therapy, showing a great evolution on alveolar healing (arrow). (E) Twelve months after treatment with 
laser therapy, which shows the final rehabilitation with fixed dental prosthesis, complete healing and no signal of necrosis.     
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